Natixis Bleichroder Upgrades Integra LifeSciences (IART) to Buy
More News related to IART
- Radiosurgery Clinicians Present Latest Advances in Brain and Spine Tumor Treatments Using Integra LifeSciences Radionics XKnife System
- Integra LifeSciences (IART) Appoints Gabrielle Wolfson as Chief Information Officer
- Integra LifeSciences Names Gabrielle Wolfson Chief Information Officer
- Integra LifeSciences (IART) Reports Mixed Q2 Earnings; Revises Q3/Q4/FY08 Guidance
- Integra LifeSciences Reports Second Quarter 2008 Financial Results
More News related to Upgrades
- PG&E Purchases More Renewable Wind Energy to Serve California Customers
- Government of Canada Invests in Moose Jaw to Help Newcomers Succeed
- Looking for Things to Do or Great City Tips? Real People Tell All in City Spice
- Looking for Things to Do or Great City Tips? Real People Tell All in City Spice
- Fitch Confirms Texas Children's Hospital Bds at 'AA'; Stable Outlook; Confirms 'F1+' on 1999B-1 Bds
Natixis Bleichroder upgrades Integra LifeSciences Holdings Corp. (Nasdaq: IART) from Hold to Buy with a $54 price target.
Integra LifeSciences Holdings Corporation engages in the development, manufacture, and marketing of surgical implants and medical instruments used primarily in neurosurgery, extremity reconstruction, orthopedics, and general surgery.
Related Categories
UpgradesStocks Mentioned
-0.23Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
